These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36008486)

  • 1. Elucidating the path to Plasmodium prolyl-tRNA synthetase inhibitors that overcome halofuginone resistance.
    Tye MA; Payne NC; Johansson C; Singh K; Santos SA; Fagbami L; Pant A; Sylvester K; Luth MR; Marques S; Whitman M; Mota MM; Winzeler EA; Lukens AK; Derbyshire ER; Oppermann U; Wirth DF; Mazitschek R
    Nat Commun; 2022 Aug; 13(1):4976. PubMed ID: 36008486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogs.
    Herman JD; Pepper LR; Cortese JF; Estiu G; Galinsky K; Zuzarte-Luis V; Derbyshire ER; Ribacke U; Lukens AK; Santos SA; Patel V; Clish CB; Sullivan WJ; Zhou H; Bopp SE; Schimmel P; Lindquist S; Clardy J; Mota MM; Keller TL; Whitman M; Wiest O; Wirth DF; Mazitschek R
    Sci Transl Med; 2015 May; 7(288):288ra77. PubMed ID: 25995223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural and functional analysis of the anti-malarial drug target prolyl-tRNA synthetase.
    Jain V; Kikuchi H; Oshima Y; Sharma A; Yogavel M
    J Struct Funct Genomics; 2014 Dec; 15(4):181-90. PubMed ID: 25047712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure of Prolyl-tRNA Synthetase-Halofuginone Complex Provides Basis for Development of Drugs against Malaria and Toxoplasmosis.
    Jain V; Yogavel M; Oshima Y; Kikuchi H; Touquet B; Hakimi MA; Sharma A
    Structure; 2015 May; 23(5):819-829. PubMed ID: 25817387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The growing pipeline of natural aminoacyl-tRNA synthetase inhibitors for malaria treatment.
    Saint-Léger A; Sinadinos C; Ribas de Pouplana L
    Bioengineered; 2016 Apr; 7(2):60-4. PubMed ID: 26963157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Selective Novel Hits against
    Nyamai DW; Tastan Bishop Ö
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical and Structural Characterization of Selective Allosteric Inhibitors of the Plasmodium falciparum Drug Target, Prolyl-tRNA-synthetase.
    Hewitt SN; Dranow DM; Horst BG; Abendroth JA; Forte B; Hallyburton I; Jansen C; Baragaña B; Choi R; Rivas KL; Hulverson MA; Dumais M; Edwards TE; Lorimer DD; Fairlamb AH; Gray DW; Read KD; Lehane AM; Kirk K; Myler PJ; Wernimont A; Walpole C; Stacy R; Barrett LK; Gilbert IH; Van Voorhis WC
    ACS Infect Dis; 2017 Jan; 3(1):34-44. PubMed ID: 27798837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of an apicoplastic aminoacyl-tRNA synthetase from Plasmodium falciparum.
    Hoen R; Novoa EM; López A; Camacho N; Cubells L; Vieira P; Santos M; Marin-Garcia P; Bautista JM; Cortés A; Ribas de Pouplana L; Royo M
    Chembiochem; 2013 Mar; 14(4):499-509. PubMed ID: 23444099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformational changes in human prolyl-tRNA synthetase upon binding of the substrates proline and ATP and the inhibitor halofuginone.
    Son J; Lee EH; Park M; Kim JH; Kim J; Kim S; Jeon YH; Hwang KY
    Acta Crystallogr D Biol Crystallogr; 2013 Oct; 69(Pt 10):2136-45. PubMed ID: 24100331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural analyses of the malaria parasite aminoacyl-tRNA synthetases provide new avenues for antimalarial drug discovery.
    Chhibber-Goel J; Yogavel M; Sharma A
    Protein Sci; 2021 Sep; 30(9):1793-1803. PubMed ID: 34184352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aminoacyl tRNA synthetases as malarial drug targets: a comparative bioinformatics study.
    Nyamai DW; Tastan Bishop Ö
    Malar J; 2019 Feb; 18(1):34. PubMed ID: 30728021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring dual inhibitory role of febrifugine analogues against Plasmodium utilizing structure-based virtual screening and molecular dynamic simulation.
    Pandey RK; Narula A; Naskar M; Srivastava S; Verma P; Malik R; Shah P; Prajapati VK
    J Biomol Struct Dyn; 2017 Mar; 35(4):791-804. PubMed ID: 26984239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repositioning and Characterization of 1-(Pyridin-4-yl)pyrrolidin-2-one Derivatives as
    Okaniwa M; Shibata A; Ochida A; Akao Y; White KL; Shackleford DM; Duffy S; Lucantoni L; Dey S; Striepen J; Yeo T; Mok S; Aguiar ACC; Sturm A; Crespo B; Sanz LM; Churchyard A; Baum J; Pereira DB; Guido RVC; Dechering KJ; Wittlin S; Uhlemann AC; Fidock DA; Niles JC; Avery VM; Charman SA; Laleu B
    ACS Infect Dis; 2021 Jun; 7(6):1680-1689. PubMed ID: 33929818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATP-directed capture of bioactive herbal-based medicine on human tRNA synthetase.
    Zhou H; Sun L; Yang XL; Schimmel P
    Nature; 2013 Feb; 494(7435):121-4. PubMed ID: 23263184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Aminoacyl tRNA Synthetases for Antimalarial Drug Development.
    Xie SC; Griffin MDW; Winzeler EA; Ribas de Pouplana L; Tilley L
    Annu Rev Microbiol; 2023 Sep; 77():111-129. PubMed ID: 37018842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repurposing DrugBank compounds as potential Plasmodium falciparum class 1a aminoacyl tRNA synthetase multi-stage pan-inhibitors with a specific focus on mitomycin.
    Olotu F; Tali MBT; Chepsiror C; Sheik Amamuddy O; Boyom FF; Tastan Bishop Ö
    Int J Parasitol Drugs Drug Resist; 2024 Aug; 25():100548. PubMed ID: 38805932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Adaptive Proline Response in P. falciparum Is Independent of PfeIK1 and eIF2α Signaling.
    Fagbami L; Deik AA; Singh K; Santos SA; Herman JD; Bopp SE; Lukens AK; Clish CB; Wirth DF; Mazitschek R
    ACS Infect Dis; 2019 Apr; 5(4):515-520. PubMed ID: 30773881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic analysis of single nucleotide polymorphisms in malaria parasite drug targets.
    Gill J; Sharma A
    Parasit Vectors; 2022 Aug; 15(1):309. PubMed ID: 36042490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformational heterogeneity in apo and drug-bound structures of Toxoplasma gondii prolyl-tRNA synthetase.
    Mishra S; Malhotra N; Kumari S; Sato M; Kikuchi H; Yogavel M; Sharma A
    Acta Crystallogr F Struct Biol Commun; 2019 Nov; 75(Pt 11):714-724. PubMed ID: 31702585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analogs of natural aminoacyl-tRNA synthetase inhibitors clear malaria in vivo.
    Novoa EM; Camacho N; Tor A; Wilkinson B; Moss S; Marín-García P; Azcárate IG; Bautista JM; Mirando AC; Francklyn CS; Varon S; Royo M; Cortés A; Ribas de Pouplana L
    Proc Natl Acad Sci U S A; 2014 Dec; 111(51):E5508-17. PubMed ID: 25489076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.